AU2001286557A1 - Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists - Google Patents
Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonistsInfo
- Publication number
- AU2001286557A1 AU2001286557A1 AU2001286557A AU8655701A AU2001286557A1 AU 2001286557 A1 AU2001286557 A1 AU 2001286557A1 AU 2001286557 A AU2001286557 A AU 2001286557A AU 8655701 A AU8655701 A AU 8655701A AU 2001286557 A1 AU2001286557 A1 AU 2001286557A1
- Authority
- AU
- Australia
- Prior art keywords
- prostanoid
- treating
- receptor antagonists
- urinary incontinence
- preventing urinary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000012506 Prostanoid EP1 receptors Human genes 0.000 title 1
- 108050002104 Prostanoid EP1 receptors Proteins 0.000 title 1
- 206010046543 Urinary incontinence Diseases 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22718300P | 2000-08-23 | 2000-08-23 | |
US60227183 | 2000-08-23 | ||
PCT/US2001/025982 WO2002015902A1 (en) | 2000-08-23 | 2001-08-20 | Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001286557A1 true AU2001286557A1 (en) | 2002-03-04 |
Family
ID=22852093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001286557A Abandoned AU2001286557A1 (en) | 2000-08-23 | 2001-08-20 | Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists |
Country Status (3)
Country | Link |
---|---|
US (1) | US20020137746A1 (en) |
AU (1) | AU2001286557A1 (en) |
WO (1) | WO2002015902A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
ITMI20010733A1 (en) * | 2001-04-05 | 2002-10-05 | Recordati Chem Pharm | USE OF ISOENZIN COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE |
WO2003070233A1 (en) * | 2002-02-19 | 2003-08-28 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
WO2004074843A1 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep1 (prostaglandin e2 ep1) |
GB0306329D0 (en) * | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Compounds |
GB0317500D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Treatment of bph |
JP2007509896A (en) * | 2003-11-03 | 2007-04-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical composition containing β-3-adrenoceptor agonist and α antagonist and / or 5-α reductase inhibitor |
DE10356112A1 (en) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | A pharmaceutical composition of a beta-3 adrenoceptor agonist and a progglandin metabolite |
JP4888775B2 (en) * | 2004-08-10 | 2012-02-29 | 小野薬品工業株式会社 | Preventive and / or therapeutic agent for lower urinary tract disease comprising EP4 agonist |
EP1889612A3 (en) * | 2006-07-24 | 2008-03-19 | Jan Kees Piet Bruinstroop | Method for controlling micturition |
TW200904437A (en) * | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
RU2452479C2 (en) | 2007-02-16 | 2012-06-10 | Оно Фармасьютикал Ко., Лтд. | Therapeutic agent in disturbed urination |
KR20100122512A (en) | 2008-07-17 | 2010-11-22 | 아사히 가세이 파마 가부시키가이샤 | Bicyclic nitrogen-containing heterocyclic compounds |
JPWO2010007943A1 (en) | 2008-07-17 | 2012-01-05 | 旭化成ファーマ株式会社 | Nitrogen-containing heterocyclic compounds |
US9532959B2 (en) * | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US10010514B2 (en) * | 2010-07-08 | 2018-07-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
EP2870138B1 (en) * | 2012-07-06 | 2018-08-22 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
US10105328B2 (en) | 2014-06-06 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
NZ768373A (en) | 2014-10-06 | 2024-03-22 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2017173274A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US10570115B2 (en) | 2016-09-30 | 2020-02-25 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
AU2017371200B2 (en) | 2016-12-09 | 2021-05-06 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
BR112020000941A2 (en) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | treatment methods for cystic fibrosis |
ES2912657T3 (en) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Processes for preparing pyrrolidine compounds |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
KR20200097293A (en) | 2017-12-08 | 2020-08-18 | 버텍스 파마슈티칼스 인코포레이티드 | Method for producing a modulator of cystic fibrosis transmembrane conduction modulator |
TWI810243B (en) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | Pharmaceutical compositions for treating cystic fibrosis |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US11993580B1 (en) | 2022-12-02 | 2024-05-28 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL108841A0 (en) * | 1993-03-10 | 1994-06-24 | Pfizer Res & Dev | Benzopyrans |
SG72827A1 (en) * | 1997-06-23 | 2000-05-23 | Hoffmann La Roche | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives |
-
2001
- 2001-08-20 AU AU2001286557A patent/AU2001286557A1/en not_active Abandoned
- 2001-08-20 WO PCT/US2001/025982 patent/WO2002015902A1/en active Application Filing
- 2001-08-23 US US09/935,614 patent/US20020137746A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002015902A1 (en) | 2002-02-28 |
US20020137746A1 (en) | 2002-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001286557A1 (en) | Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists | |
AU2001275257A1 (en) | Methods and devices for the treatment of urinary incontinence | |
AU2002334833A1 (en) | Urethral support for incontinence | |
MXPA03002276A (en) | Urinary incontinence device and method of making same. | |
AU5204900A (en) | Flushing method of toilet, toilet used for carrying out said method and components thereof | |
AU2001288825A1 (en) | Bulking agent delivery method for treating incontinence | |
AU2002342707A1 (en) | Combination of selected opioids with muscarine antagonists for treating urinary incontinence | |
AU2002336405A1 (en) | Methods for treating deodorizer distillate | |
IL158050A0 (en) | Use of selective cox-2 inhibitors for the treatment of urinary incontinence | |
AU7360700A (en) | Methods and compositions for preventing and treating urinary tract disorders | |
AU2001243445A1 (en) | Intra-urethral device for incontinence and method for making and using same | |
AU2002227449A1 (en) | Control of urinary continence | |
AU2003214273A1 (en) | Improved system for the treatment of stress urinary incontinence | |
HUP0200738A3 (en) | Method of the treatment of incontinence | |
AU4552200A (en) | Method of treating psychotic disorders | |
AU2002233210A1 (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontinence | |
AUPQ968700A0 (en) | Treatment of urinary incontinence | |
AU2001233581A1 (en) | Process for reserving and treating urine | |
AU2002223688A1 (en) | Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence | |
AU2002233209A1 (en) | Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence | |
HUP0303268A3 (en) | Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence | |
AU2001261513A1 (en) | Composition and method for increasing testosterone levels | |
HUP0104514A2 (en) | The use of aril-substituted cyclobutylalkylamines for treating urinary incontinence | |
AU2001238288A1 (en) | Method and compositions for treating fibrotic diseases | |
AU1196601A (en) | Methods of diagnosing and treating urinary incontinence |